Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns.

Lalevée S, Audureau E, Riou A, Colin A, Anquetin M, Barau C, Valeyrie-Allanore L, Delfau-Larue MH, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S, Hüe S.

Clin Exp Allergy. 2019 Jun 17. doi: 10.1111/cea.13449. [Epub ahead of print]

PMID:
31206897
2.

Acute exanthemas: a prospective study of 98 adult patients with emphasis of cytokinic and metagenomic investigation.

Deschamps O, Ortonne N, Hüe S, Rodriguez C, Deschodt C, Hirsch G, Colin A, Grégoire L, Delfau-Larue MH, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S.

Br J Dermatol. 2019 May 25. doi: 10.1111/bjd.18166. [Epub ahead of print]

PMID:
31127953
3.

Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.

Armand ML, Taieb C, Bourgeois A, Bourlier M, Bennani M, Bodemer C, Wolkenstein P; along with the French national network on rare skin diseases (FIMARAD).

Orphanet J Rare Dis. 2019 May 3;14(1):94. doi: 10.1186/s13023-019-1067-8.

4.

Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae.

Hajj C, Ezzedine K, Thorel D, Delcampe A, Royer G, Hua C, Colin A, de Prost N, Muraine M, Chosidow O, Wolkenstein P, Gueudry J, Ingen-Housz-Oro S.

Br J Dermatol. 2019 Apr 23. doi: 10.1111/bjd.18023. [Epub ahead of print] No abstract available.

PMID:
31016732
5.

PAPASH, PsAPASH and PASS autoinflammatory syndromes: Phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens.

Gottlieb J, Madrange M, Gardair C, Sbidian E, Frazier A, Wolkenstein P, Hickman G, Schneider P, Baudry C, Claudepierre P, Bertheau P, Richette P, Smahi A, Bachelez H.

Br J Dermatol. 2019 Apr 13. doi: 10.1111/bjd.18003. [Epub ahead of print]

PMID:
30980721
6.

First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.

Rauen KA, Alsaegh A, Ben-Shachar S, Berman Y, Blakeley J, Cordeiro I, Elgersma Y, Evans DG, Fisher MJ, Frayling IM, George J, Huson SM, Kerr B, Khire U, Korf B, Legius E, Messiaen L, van Minkelen R, Nampoothiri S, Ngeow J, Parada LF, Phadke S, Pillai A, Plotkin SR, Puri R, Raji A, Ramesh V, Ratner N, Shankar SP, Sharda S, Tambe A, Vikkula M, Widemann BC, Wolkenstein P, Upadhyaya M.

Am J Med Genet A. 2019 Jun;179(6):1091-1097. doi: 10.1002/ajmg.a.61125. Epub 2019 Mar 25.

PMID:
30908877
7.

Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases.

Lecadet A, Woerther PL, Hua C, Colin A, Gomart C, Decousser JW, Mekontso Dessap A, Wolkenstein P, Chosidow O, de Prost N, Ingen-Housz-Oro S.

J Am Acad Dermatol. 2019 Mar 16. pii: S0190-9622(19)30444-X. doi: 10.1016/j.jaad.2019.03.030. [Epub ahead of print]

PMID:
30890340
8.

Cervical cutaneous sclerosis: the stomach is not far from the skin.

Gauci ML, Hua C, Ortonne N, Boussion H, Zehou O, Wolkenstein P, Chosidow O.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e177-e179. doi: 10.1111/jdv.15432. Epub 2019 Feb 18. No abstract available.

PMID:
30653760
9.

Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Thorel D, Delcampe A, Ingen-Housz-Oro S, Hajj C, Gabison E, Chosidow O, Wolkenstein P, Royer G, Ezzedine K, Muraine M, Gueudry J.

Br J Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17627. [Epub ahead of print] No abstract available.

PMID:
30633324
10.

Severe contact allergy to mupirocin in a polysensitized patient.

Assier H, Hirsch G, Wolkenstein P, Chosidow O.

Contact Dermatitis. 2019 Jun;80(6):397-398. doi: 10.1111/cod.13208. Epub 2019 Feb 22. No abstract available.

PMID:
30624771
11.

Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation.

Frayling IM, Mautner VF, van Minkelen R, Kallionpaa RA, Aktaş S, Baralle D, Ben-Shachar S, Callaway A, Cox H, Eccles DM, Ferkal S, LaDuca H, Lázaro C, Rogers MT, Stuenkel AJ, Summerour P, Varan A, Yap YS, Zehou O, Peltonen J, Evans DG, Wolkenstein P, Upadhyaya M.

J Med Genet. 2019 Apr;56(4):209-219. doi: 10.1136/jmedgenet-2018-105599. Epub 2018 Dec 10.

PMID:
30530636
12.

Prevalence and Description of Hidradenitis Suppurativa in Down Syndrome: A Cross-sectional Study of 783 Subjects.

Poizeau F, Sbidian E, Mircher C, Rebillat AS, Chosidow O, Wolkenstein P, Ravel A, Hotz C.

Acta Derm Venereol. 2019 Mar 1;99(3):351-352. doi: 10.2340/00015555-3095. No abstract available.

13.

Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series.

Gendreau S, Amiot A, Le Baleur Y, Charpy C, Wolkenstein P, Chosidow O, Mekontso Dessap A, Ingen-Housz-Oro S, de Prost N.

Br J Dermatol. 2019 May;180(5):1234-1235. doi: 10.1111/bjd.17428. Epub 2019 Feb 13. No abstract available.

PMID:
30430542
14.

Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics.

Chaby G, Ingen-Housz-Oro S, De Prost N, Wolkenstein P, Chosidow O, Fardet L.

J Am Acad Dermatol. 2019 May;80(5):1453-1455. doi: 10.1016/j.jaad.2018.10.058. Epub 2018 Nov 2. No abstract available.

PMID:
30395917
15.

Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells.

Radomska KJ, Coulpier F, Gresset A, Schmitt A, Debbiche A, Lemoine S, Wolkenstein P, Vallat JM, Charnay P, Topilko P.

Cancer Discov. 2019 Jan;9(1):130-147. doi: 10.1158/2159-8290.CD-18-0156. Epub 2018 Oct 22.

PMID:
30348676
16.

Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial.

Zehou O, Ferkal S, Brugieres P, Barbarot S, Bastuji-Garin S, Combemale P, Valeyrie-Allanore L, Sbidian E, Wolkenstein P.

J Invest Dermatol. 2019 Mar;139(3):718-720. doi: 10.1016/j.jid.2018.09.016. Epub 2018 Oct 16. No abstract available.

PMID:
30339775
17.

Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge.

Lalevee S, Ortonne N, Hotz C, Schlemmer F, Beldi-Ferchiou A, Delfau-Larue MH, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S.

Eur J Dermatol. 2018 Dec 1;28(6):834-835. doi: 10.1684/ejd.2018.3410. No abstract available.

PMID:
30325315
18.

Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance.

Chaby G, Lebrun-Vignes B, Haddad C, Hemery F, Ingen-Housz-Oro S, de Prost N, Wolkenstein P, Chosidow O, Fardet L.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1344-1346. doi: 10.1016/j.jaip.2018.09.028. Epub 2018 Oct 5. No abstract available.

PMID:
30292922
19.

Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients.

Hefez L, Zaghbib K, Sbidian E, Valeyrie-Allanore L, Allain M, Duong TA, Colin A, Bellivier F, Romano H, de Prost N, Chazelas K, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S.

Br J Dermatol. 2019 May;180(5):1206-1213. doi: 10.1111/bjd.17267. Epub 2018 Dec 3.

PMID:
30282109
20.

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.

Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, Azoulay D, Salloum C, Laurent A, de la Taille A, Salomon L, Cholley I, Haioun C, Dupuis J, Wolkenstein P, Matignon MB, Grimbert P, Tournigand C.

Int J Cancer. 2019 Feb 15;144(4):886-896. doi: 10.1002/ijc.31769. Epub 2018 Nov 20.

PMID:
30155929
21.

Association Between Severe Acute Contact Dermatitis Due to Nigella sativa Oil and Epidermal Apoptosis.

Gaudin O, Toukal F, Hua C, Ortonne N, Assier H, Jannic A, Giménez-Arnau E, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S.

JAMA Dermatol. 2018 Sep 1;154(9):1062-1065. doi: 10.1001/jamadermatol.2018.2120.

PMID:
30073256
22.

Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis: Results From the NutriNet-Santé Cohort.

Phan C, Touvier M, Kesse-Guyot E, Adjibade M, Hercberg S, Wolkenstein P, Chosidow O, Ezzedine K, Sbidian E.

JAMA Dermatol. 2018 Sep 1;154(9):1017-1024. doi: 10.1001/jamadermatol.2018.2127.

PMID:
30046840
23.

The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.

Brosseau JP, Pichard DC, Legius EH, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma SK, Brownell I, Le LQ.

Neurology. 2018 Jul 10;91(2 Supplement 1):S14-S20. doi: 10.1212/WNL.0000000000005788.

PMID:
29987131
24.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Supplement 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
25.

Creating a comprehensive research strategy for cutaneous neurofibromas.

Blakeley JO, Wolkenstein P, Widemann BC, Lee J, Le LQ, Jackson R, Stathis M, Verma SK.

Neurology. 2018 Jul 10;91(2 Supplement 1):S1-S4. doi: 10.1212/WNL.0000000000005789.

PMID:
29987129
26.

A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices.

Kechichian E, Ingen-Housz-Oro S, Sbidian E, Hemery F, Bernier C, Fite C, Delaunay J, Staumont-Sallé D, Toukal F, Dupin N, Abasq C, Samimi M, Picard C, Hebert V, Prost C, Monfort JB, Milpied B, Wolkenstein P, Chosidow O.

Br J Dermatol. 2018 Oct;179(4):1009-1011. doi: 10.1111/bjd.16928. Epub 2018 Aug 16. No abstract available.

PMID:
29957881
27.

[Pemphigus and herpes: Multicentre survey and literature review].

Merlant M, Seta V, Bernard P, Fourati S, Meritet JF, Wolkenstein P, Dupin N, Joly P, Chosidow O, Ingen-Housz-Oro S.

Ann Dermatol Venereol. 2018 Aug - Sep;145(8-9):477-485. doi: 10.1016/j.annder.2018.03.169. Epub 2018 Jun 14. Review. French.

PMID:
29866471
28.

Very late sensitization to parabens induced by repeated applications of an anaesthetic therapeutic plaster to non-damaged skin.

Assier H, Wolkenstein P, Chosidow O.

Contact Dermatitis. 2018 Sep;79(3):194-195. doi: 10.1111/cod.13029. Epub 2018 May 23. No abstract available.

PMID:
29790180
29.

Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing.

El Khoury M, Assier H, Gener G, Paul M, Haddad C, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S.

Br J Dermatol. 2018 Oct;179(4):978-979. doi: 10.1111/bjd.16738. Epub 2018 Jul 20. No abstract available.

PMID:
29747236
30.

[Treatment of severe cutaneous adverse drug reactions].

Ingen-Housz-Oro S, Duong TA, de Prost N, Colin A, Fardet L, Lebrun-Vignes B, Barbaud A, Chosidow O, Wolkenstein P; centre de référence des dermatoses bulleuses toxiques et toxidermies graves et le FISARD.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):454-464. doi: 10.1016/j.annder.2018.02.014. Epub 2018 Apr 13. French. No abstract available.

PMID:
29657073
31.

Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins).

Ingen-Housz-Oro S, Duong TA, Bensaid B, Bellon N, de Prost N, Lu D, Lebrun-Vignes B, Gueudry J, Bequignon E, Zaghbib K, Royer G, Colin A, Do-Pham G, Bodemer C, Ortonne N, Barbaud A, Fardet L, Chosidow O, Wolkenstein P; French National Reference Center for Toxic Bullous Dermatoses.

Orphanet J Rare Dis. 2018 Apr 10;13(1):56. doi: 10.1186/s13023-018-0793-7.

32.

Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes.

Amode R, Ingen-Housz-Oro S, Ortonne N, Bounfour T, Pereyre S, Schlemmer F, Bequignon E, Royer G, Wolkenstein P, Chosidow O.

J Am Acad Dermatol. 2018 Jul;79(1):110-117. doi: 10.1016/j.jaad.2018.03.013. Epub 2018 Mar 17.

PMID:
29559400
33.

[Association of chromhidrosis and segmental neurofibromatosis].

Velter C, Thubert S, Wolkenstein P, Le Cleach L.

Presse Med. 2018 Mar;47(3):294-296. doi: 10.1016/j.lpm.2018.01.001. Epub 2018 Mar 9. French. No abstract available.

PMID:
29530298
34.

Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that 'toxic' epidermal necrolysis can be 'non-toxic'.

Dumas M, Hua C, Hotz C, Velter C, Duong TA, Maraffi T, Ortonne N, Hüe S, Fardet L, de Prost N, Wolkenstein P, Ingen-Housz-Oro S, Chosidow O.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):e360-e361. doi: 10.1111/jdv.14935. Epub 2018 Mar 30. No abstract available.

PMID:
29524279
35.

Bladder Dysfunction in Children with Neurofibromatosis Type I: Report of Four Cases and Review of the Literature.

Bouty A, Dobremez E, Harper L, Harambat J, Bouteiller C, Zaghet B, Wolkenstein P, Ducassou S, Lefevre Y.

Urol Int. 2018;100(3):339-345. doi: 10.1159/000487193. Epub 2018 Mar 7. Review.

PMID:
29514154
36.

Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme.

Drahy F, Ingen-Housz-Oro S, Grootenboer-Mignot S, Wolkenstein P, Chosidow O.

JAMA Dermatol. 2018 Apr 1;154(4):487-489. doi: 10.1001/jamadermatol.2017.5889. No abstract available.

PMID:
29450445
37.

Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.

Poizeau F, Gaudin O, Le Cleach L, Duong TA, Hua C, Hotz C, Ingen-Housz-Oro S, Sbidian E, Zehou O, Colin A, de Prost N, Lebrun-Vignes B, Chosidow O, Wolkenstein P, Fardet L.

J Invest Dermatol. 2018 Jun;138(6):1293-1300. doi: 10.1016/j.jid.2017.12.034. Epub 2018 Jan 31.

38.

High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series.

Bardo-Brouard P, Luizard C, Valeyrie-Allanore L, Goujon C, Do B, Colin A, Wolkenstein P, Paul M.

Curr Med Res Opin. 2018 May;34(5):887-891. doi: 10.1080/03007995.2018.1433142. Epub 2018 Feb 21.

PMID:
29368950
39.

Severe cutaneous adverse reactions due to inappropriate medication use.

Chaby G, Valeyrie-Allanore L, Duong TA, Lebrun-Vignes B, Milpied B, Sassolas B, Tetart F, Wolkenstein P, Chosidow O, Fardet L.

Br J Dermatol. 2018 Aug;179(2):329-336. doi: 10.1111/bjd.16365. Epub 2018 May 14.

PMID:
29352771
40.

Stevens-Johnson Syndrome During Pregnancy: Case Report of a Newborn Treated With the Culprit Drug.

Velter C, Hotz C, Ingen-Housz-Oro S, Wolkenstein P, Fardet L.

JAMA Dermatol. 2018 Feb 1;154(2):224-225. doi: 10.1001/jamadermatol.2017.4607. No abstract available.

PMID:
29261833
41.

Acne across Europe: an online survey on perceptions and management of acne.

Szepietowski JC, Wolkenstein P, Veraldi S, Tennstedt D, Machovcová A, Delarue A.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):463-466. doi: 10.1111/jdv.14719. Epub 2017 Dec 18.

PMID:
29194802
42.

Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases.

Lu D, Hua C, Servy A, Foulet F, Botterel F, De Prost N, Ellrodt O, Sigha B, Popescu D, Ortonne N, Wolkenstein P, Ingen-Housz-Oro S, Chosidow O.

Eur J Dermatol. 2018 Apr 1;28(2):227-229. doi: 10.1684/ejd.2017.3212. No abstract available.

PMID:
29171398
43.

Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.

Giamarellos-Bourboulis EJ, Sobell J, Ryan C, Wolkenstein PJ, Geng Z, Mulder GD.

Wounds. 2017 Nov;29(11):E98-E102.

44.

Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients.

Hurabielle C, Sbidian E, Beltraminelli H, Bouchindhomme B, Chassagne-Clément C, Balme B, Bossard C, Delfau-Larue MH, Wolkenstein P, Chosidow O, Cordonnier C, Toma A, Pautas C, Ortonne N.

Hum Pathol. 2018 Jan;71:100-108. doi: 10.1016/j.humpath.2017.10.018. Epub 2017 Oct 28.

PMID:
29107664
45.

Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases.

Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):437-440. doi: 10.1111/jdv.14646. Epub 2017 Nov 7.

PMID:
29055135
46.

Hemostasis and Type 1 Neurofibromatosis.

Niddam J, Matheron C, La Padula S, Wolkenstein P, Meningaud JP.

Plast Reconstr Surg Glob Open. 2017 Jul 26;5(7):e1414. doi: 10.1097/GOX.0000000000001414. eCollection 2017 Jul. No abstract available.

47.

Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests.

Assier H, Valeyrie-Allanore L, Gener G, Verlinde Carvalh M, Chosidow O, Wolkenstein P.

Contact Dermatitis. 2017 Nov;77(5):297-302. doi: 10.1111/cod.12842. Epub 2017 Jul 21.

PMID:
28730661
48.

Severe sequelae of erythema multiforme: three cases.

Viarnaud A, Ingen-Housz-Oro S, Marque M, Valeyrie-Allanore L, Ortonne N, Gueudry J, Grootenboer-Mignot S, Muraine M, Bequignon E, Gagnière C, Schlemmer F, Wolkenstein P, Chosidow O.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e34-e36. doi: 10.1111/jdv.14478. Epub 2017 Sep 6. No abstract available.

PMID:
28710842
49.

Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries.

Wolkenstein P, Machovcová A, Szepietowski JC, Tennstedt D, Veraldi S, Delarue A.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):298-306. doi: 10.1111/jdv.14475. Epub 2017 Sep 6.

50.

Agreement Between Self-reported Inflammatory Skin Disorders and Dermatologists' Diagnosis: A Cross-sectional Diagnostic Study.

Phan C, Ezzedine K, Lai C, Le Cleach L, Cogrel O, Fardet L, Wolkenstein P, Chosidow O, Beylot-Barry M, Sbidian E.

Acta Derm Venereol. 2017 Nov 15;97(10):1243-1244. doi: 10.2340/00015555-2749. No abstract available.

Supplemental Content

Loading ...
Support Center